The human transmembrane 6 superfamily member 2 (TM6SF2) gene has been implicated in plasma lipoprotein metabolism, alcoholic and non-alcoholic fatty liver disease and myocardial infarction in multiple genome-wide association studies. To investigate the role of Tm6sf2 in metabolic homeostasis, we generated mice with elevated expression using adeno-associated virus (AAV)-mediated gene delivery. Hepatic overexpression of mouse Tm6sf2 resulted in phenotypes previously observed in Tm6sf2-deficient mice including reduced plasma lipid levels, diminished hepatic triglycerides secretion and increased hepatosteatosis. Furthermore, increased hepatic Tm6sf2 expression protected against the development of atherosclerosis in LDLreceptor/ApoB48-deficient mice. In cultured human hepatocytes, Tm6sf2 overexpression reduced apolipoprotein B secretion and resulted in its accumulation within the endoplasmic reticulum (ER) suggesting impaired ER-to-Golgi trafficking of prevery low-density lipoprotein (VLDL) particles. Analysis of two metabolic trait-associated coding polymorphisms in the human TM6SF2 gene (rs58542926 and rs187429064) revealed that both variants impact TM6SF2 expression by affecting the rate of protein turnover. These data demonstrate that rs58542926 (E167K) and rs187429064 (L156P) are functional variants and suggest 
Introduction
Genome-wide association studies uncovered hundreds of chromosomal regions associated with metabolic traits and diseases in human populations. Plasma lipoprotein levels are determined by genetic variation at over 150 loci, most of which have not been implicated in lipid metabolism before (1) . Thus, characterization of genes and polymorphisms underlying these loci may offer novel mechanistic insights into metabolic regulation and dysfunction.
One of the most widely replicated chromosomal regions associated with metabolic traits is the CILP2 (a.k.a. NCAN or PBX4) locus at 19p13.11, which has been linked to variation in fasting and postprandial plasma lipid levels, alcoholic and nonalcoholic fatty liver disease (NAFLD), type 2 diabetes and coronary artery disease (1) (2) (3) (4) (5) (6) (7) (8) (9) . Of the more than dozen genes located within the 19p13.11 critical genomic interval, transmembrane 6 superfamily member 2 (TM6SF2) has emerged as a candidate for underlying metabolic trait associations at this locus. Genetic studies identified two missense single nucleotide polymorphisms (SNPs) in the TM6SF2 gene, E167K (rs58542926) and L156P (rs187429064), as independent determinants of plasma cholesterol and triglycerides (TG) levels (3, 5) . Moreover, E167K has been linked with several NAFLD-related phenotypes including elevated liver enzymes, hepatic steatosis and fibrosis, as well as alcohol-induced cirrhosis and hepatocellular carcinoma (8, (10) (11) (12) (13) (14) .
TM6SF2 is predominantly expressed in tissues associated with the production of apolipoprotein B (APOB)-lipoproteins including liver, small intestine and kidney suggesting a potential role in lipoprotein metabolism (3) . Indeed, mice with wholebody or liver-specific Tm6sf2 deficiency exhibited low plasma and elevated hepatic lipid levels likely due to reduced hepatic TG secretion (3, 15) . Furthermore, tm6sf2 loss-of-function in zebrafish leads to decreased low-density lipoprotein (LDL)-cholesterol and hepatic steatosis (9) . Consistent with these studies, knock-down of TM6SF2 in hepatoma cell lines suppressed TGsecretion and resulted in intracellular TG accumulation (16) . However, studies in mouse models with elevated expression of TM6SF2 produced conflicting results. Transgenic overexpression of TM6SF2 using an albumin promoter was associated with excess hepatic lipid accumulation, similar to the effect of Tm6sf2 deficiency (17) . Furthermore, plasma TG levels were unaffected or decreased in TM6SF2 transgenic mice on chow or high-fat diets, respectively, whereas adenoviral overexpression resulted in elevated plasma lipids (2, 17) . Thus, while its involvement in lipid metabolism is now well established, the role of TM6SF2 expression in the regulation of plasma and hepatic lipid traits is incompletely understood.
TM6SF2 is a multi-pass membrane protein localized to the endoplasmic reticulum (ER) and ER-Golgi intermediate compartment (ERGIC) (3, 15) . On the basis of sequence similarity to Emopamil-binding protein, an enzyme with sterol isomerase activity, TM6SF2 has been hypothesized to play a role in sterol biosynthesis (18) and a recent study provided experimental evidence consistent with this hypothesis (17) . Alternatively, it has been proposed that Tm6sf2 is involved in the transfer of neutral lipids from cytoplasmic to luminal lipid droplets or very lowdensity lipoprotein (VLDL) particles (15) . Although its exact molecular function remains to be established, Tm6sf2 has emerged as a novel player in cellular lipoprotein metabolism.
Genetic studies identified two missense SNPs in the TM6SF2 gene, E167K (rs58542926) and L156P (rs187429064), as independent determinants of plasma cholesterol and TG levels (3, 5) . E167K has also been linked with several NAFLD-related phenotypes including elevated liver enzymes, hepatic steatosis and fibrosis, as well as alcohol-induced cirrhosis and hepatocellular carcinoma (8, (13) (14) (15) (16) (17) . The E167K amino acid change reduced expression of TM6SF2 protein in a previous study, but the underlying mechanism has not been investigated (3) . The potential functional impact of L156P polymorphism remains undetermined.
In the present study we generated and characterized mouse and in vitro models to assess the physiological and cellular impact of Tm6sf2 overexpression on lipoprotein metabolism and related traits. Furthermore, we investigated the molecular mechanism through which human E167K and L156P polymorphisms affect TM6SF2 expression.
Results

Hepatic overexpression of Tm6sf2 suppresses plasma lipid levels
While the plasma lipid-lowering effect of hepatic Tm6sf2 deficiency has previously been demonstrated (2, 3, 15) , the metabolic impact of elevated Tm6sf2 expression remains unclear. To investigate this issue, we employed adeno-associated virus (AAV)-mediated gene delivery using an AAV8 vector harboring the mouse Tm6sf2 cDNA driven by the thyroxine-binding globulin (TBG) promoter, which allows hepatocyte-specific expression of the transgene (19) . Relative to mice injected with empty vector (AAV-Null), mice receiving AAV-Tm6sf2 (10 12 gc/mouse) unexpectedly exhibited lower levels of plasma lipids including TG and cholesterol associated with both high-density lipoprotein (HDL) and non-HDL lipoproteins (Fig. 1A ). These differences reflect 40-60% suppression of plasma lipid concentrations in AAV-Tm6sf2-injected mice compared with pre-injection levels, whereas plasma lipids remained unchanged after AAV-Null injection (Supplementary Material, Fig. S1A ). Suppression of lipid levels by AAV-Tm6sf2 was sustained for up to 12 weeks following virus injection (Supplementary Material, Fig. S1B ). Lipoprotein separation by fast-performance liquid chromatography (FPLC) indicated that Tm6sf2 overexpression reduced TG content in the VLDL and LDL fractions, as well as cholesterol associated with the VLDL, LDL and HDL fractions (Fig. 1B) .
In light of previous studies in Tm6sf2-deficient mice the lipid-lowering effect of Tm6sf2 overexpression was paradoxical, therefore we investigated experimental parameters that may have impacted our results. As the AAV dose used in initial experiments [10 12 genome copies (gc) per mouse] produced >100-fold elevated hepatic Tm6sf2 expression over endogenous levels (Supplementary Material, Fig. S1C ;ApoB 100/100 double knock-out (DKO) mice deficient in LDL-receptor and apolipoprotein B48 (ApoB48) (20) . As expected, DKO mice injected with control virus exhibited hypercholesterolemia in the VLDL and LDL plasma fractions of both males ( Overexpression of human TM6SF2 isoform is associated with transient plasma lipid phenotypes and hepatic injury
In contrast to our results with mouse Tm6sf2, adenoviral overexpression of human TM6SF2 has previously been reported to elevate plasma TG and cholesterol levels (2) . To identify the source of conflict between studies, we evaluated the impact of human and mouse Tm6sf2 on plasma lipid phenotypes by performing a side-by-side comparison of the isoforms using identical AAV doses (i.e. 10 12 gc/mouse). Consistent with our previous results, injection of AAV-Tm6sf2 robustly and persistently lowered lipid levels, but the effect of AAV-TM6SF2 administration was transient and undetectable 4 weeks after injection ( Fig. 2A) . While TM6SF2 modestly suppressed TG levels 2 weeks post-injection, it had no effect on total or HDL-cholesterol and, in sharp contrast to Tm6sf2, increased non-HDL-cholesterol ( Fig. 2A) . These results demonstrate that the impact of human and mouse Tm6sf2 overexpression on plasma lipid levels is markedly different. To investigate whether the observed phenotypic differences between Tm6sf2 isoforms were due to differences in transgene expression, we performed a time-course analysis. Whereas expression of human and mouse Tm6sf2 were similar 1 week after AAV injection, hepatic TM6SF2 mRNA levels dropped precipitously by 2 weeks, and by 4 weeks expression of the human isoform was less than 10% of Tm6sf2 (Fig. 2B) . Moreover, 2 weeks after AAV injection TM6SF2, but not Tm6sf2, expression resulted in elevated plasma ALT activity (Fig. 2C ) and direct bilirubin level (Fig. 2D) , increased hepatic expression of the macrophage marker Cd68 (Fig. 2E ) and inflammatory cell infiltration (Supplementary Material, Fig. S2A ). The inflammatory phenotype in AAV-TM6SF2 mice was not associated with elevated ER stress; in fact several markers of the UPR were suppressed by TM6SF2 expression (Supplementary Material, Fig. S2B ). Taken together, these results suggest that acute overexpression of TM6SF2 triggers hepatitis and hepatic injury followed by the elimination of transduced cells. These data also raise the possibility that inflammation associated with TM6SF2 overexpression may confound its impact on plasma lipid phenotypes and provide a potential explanation for the conflict between our study and a previous report (2) . We used the mouse Tm6sf2 isoform in all subsequent in vivo experiments.
Tm6sf2 overexpression suppresses VLDL-TG secretion and promotes steatosis and inflammatory gene expression
As Tm6sf2 has previously been implicated in hepatic TG secretion in deficiency models (3, 15) , we next investigated if Tm6sf2 overexpression also affects this process. Eight weeks after AAV injection (10 12 gc/mouse), we measured the rate of TG accumulation in plasma in the presence of Pluronic F-127, an inhibitor of TG clearance. AAV-Tm6sf2 suppressed the rate of TG secretion by $34% relative to control (Fig. 3A) pointing to diminished hepatic VLDL-TG secretion as the mechanism responsible for the plasma TG-lowering effect of Tm6sf2 overexpression. Interestingly, cholesterol secretion remained unchanged (Supplementary Material, Fig. S3A ) suggesting that AAV-Tm6sf2 affected lipid composition of the VLDL particle. While liver morphology was indistinguishable in control and AAV-Tm6sf2-injected mice, Oil Red O (ORO) staining revealed increased neutral lipid accumulation in the latter (Fig. 3B) . Indeed, biochemical analysis demonstrated elevated hepatic TG content in AAV-Tm6sf2 mice, whereas hepatic cholesterol levels remained unaffected (Fig. 3C ). Four weeks after virus injection Tm6sf2 overexpression was also associated with modest, but detectable, elevation of plasma ALT activity likely reflecting hepatic steatosis ( (Fig. 3D) . Collectively, our results suggest that Tm6sf2 overexpression likely suppresses VLDL-TG secretion through posttranscriptional mechanisms, which may include impaired VLDL assembly or intracellular trafficking, increased VLDL degradation, decreased de novo lipogenesis or elevated FA oxidation. Furthermore, we also established that Tm6sf2 overexpression promoted hepatic steatosis and increased inflammatory and fibrogenic gene expression.
Hepatic Tm6sf2 overexpression protects against coronary artery disease
The dramatic LDL-cholesterol-lowering effect of AAV-Tm6sf2 prompted us to test whether hepatic Tm6sf2 overexpression may protect against coronary artery disease. To test this hypothesis, we fed a high-cholesterol (HC) diet to DKO mice injected with AAV-Null or AAV-Tm6sf2 vectors (10 12 gc/mouse) and assessed atherosclerotic lesions (Fig. 4A ). After 12 weeks on the HC diet, AAV-Tm6sf2-injected mice demonstrated significantly lower plasma TG (88% reduction) and cholesterol (72% reduction) levels associated with ApoB-lipoproteins, but elevated HDL-cholesterol concentrations (35% increase) relative to AAV-Null controls ( Fig. 4B and 4C ). Visual inspection of the aortic arch revealed massive lipid deposition in control mice, whereas AAV-Tm6sf2 aortas were largely devoid of atherosclerotic plaques (Fig. 4D ). Morphometric analysis of histological sections confirmed substantially reduced lesion area and ORO-stained area in the aortic arch (Fig. 4E ), whole aorta ( Fig. 4F ) and aortic sinus (Fig. 4G ) of AAV-Tm6sf2 mice. These results indicate that suppression of plasma cholesterol levels by Tm6sf2 overexpression protects against atherosclerosis in DKO mice.
Tm6sf2 overexpression suppresses APOB secretion and leads to its accumulation in the ER
Our in vivo results indicated that overexpression of Tm6sf2 reduced plasma lipid levels by diminishing the hepatic secretion of TG. To investigate the cellular mechanisms underlying this effect, we assessed the impact of Tm6sf2 overexpression on APOB metabolism in human hepatocytes. High-level overexpression of Tm6sf2 (Supplementary Material, Fig. S4A ) strongly suppressed the secretion of APOB, but not albumin, into the culture media of Huh7 cells ( Fig. S4D ).
To account for reduced APOB secretion in Tm6sf2-overexpressing cells, we considered the possibility that Tm6sf2 overexpression promotes intracellular APOB degradation, a principal process in the regulation of VLDL secretion. As limited TG availability within the ER is one of the key mechanisms triggering APOB degradation, we attempted to rescue the secretion defect in Tm6sf2-overexpressing cells by oleic acid (OA) supplementation, a treatment known to promote APOB lipidation and secretion (21) . As expected, OA treatment stimulated APOB secretion in both control and Tm6sf2-overexpressing Hep3B cells, but it failed to mitigate the inhibitory effect of Tm6sf2 overexpression (Fig. 5C, left panel) . Furthermore, MTTP activity was unaffected by Tm6sf2 overexpression (Supplementary Material, Fig. S4E ) suggesting that reduced APOB secretion was not due to impaired lipidation of nascent APOB in these cells. Next, we tested whether increased intracellular degradation of APOB played a role in the effect of Tm6sf2 overexpression on APOB secretion. Treatment with inhibitors of proteasomal (lactacystin) or autophagy (3-methyladenine) pathways of APOB degradation increased its secretion in both control and Tm6sf2-overexpressing cells (Fig. 5C, right panel) . However, neither treatment abolished the inhibitory effect of Tm6sf2 overexpression demonstrating that reduced APOB secretion was not due to increased APOB degradation. Indeed, intracellular APOB levels were 2-3-fold elevated in Huh7 cells overexpressing Tm6sf2 and similar results were observed in HepG2 cells (Fig. 5D) . Consistent with these in vitro observations, ApoB-100 and ApoB-48 levels were significantly lower in plasma (Fig. 5E) , whereas the latter showed marked accumulation in the liver of AAV-Tm6sf2 mice (Fig. 5F) .
To identify the cellular compartment of APOB accumulation in Tm6sf2-overexpressing cells, we performed sub-cellular localization studies using confocal immunofluorescence microscopy. Previous studies in rat hepatocytes demonstrated that at steady state cellular APOB is predominantly localized to the Golgi (22, 23) . In line with these results, APOB exhibited punctate staining pattern and only partial co-localization with calreticulin (CRT), an ER marker, in control Huh7 cells (Fig. 5G , upper panels). In contrast, cells overexpressing Tm6sf2 showed predominantly perinuclear staining of APOB and a high degree of co-localization with CRT demonstrating that APOB accumulated within the ER (Fig. 5G, lower panels) . Taken together, these results suggest that Tm6sf2 overexpression suppresses cellular APOB secretion by interfering with the ER-to-Golgi transport of APOB-lipoprotein particles.
Metabolic trait-associated polymorphisms reduce TM6SF2 protein expression by increasing protein turnover
Exome-wide association studies identified two coding SNPs, rs187429064 (L156P) and rs58542926 (E167K), in the human TM6SF2 gene to be associated with plasma lipid levels and NAFLD (3, 5) . While the common alleles (L156 and E167) are evolutionarily conserved and the rare alleles (P156 and K167) are predicted to be deleterious, their impact on TM6SF2 remains largely uncharacterized. To address this question, we developed Huh7 cell lines that stably express TM6SF2 isoforms representing the common and rare alleles of each polymorphism. Despite slightly elevated (P156) or similar (K167) mRNA levels ( Fig. 6A) , protein expression of both rare TM6SF2 isoforms was markedly reduced relative to the common (L156/E167) isoform (Fig. 6B) . To investigate whether P156 or K167 affects TM6SF2 turnover, we assessed the degradation of luciferase-TM6SF2 fusion proteins in the presence of the protein synthesis inhibitor, cycloheximide (CHX). Consistent with their reduced steady-state expression, the P156 and K167 isoforms exhibited significantly increased rate of degradation (t 1/2 $4.5 h) compared with common isoform (t 1/2 $9 h) (Fig. 6C ). These results demonstrate that rs58542926 and rs187429064 are functional variants at the 19p13.11 locus and affect TM6SF2 protein expression through altering its rate of turnover.
Discussion
In the present work, we employed mouse and in vitro models to investigate the role of Tm6sf2 in organismal and cellular lipid metabolism. We demonstrated that hepatic overexpression of Tm6sf2 lowers plasma lipid levels in wild-type and genetically hyperlipidemic mice, protects against atherosclerosis, and causes hepatic steatosis. Using cultured hepatocytes we established that Tm6sf2 overexpression suppresses ApoB-lipoprotein secretion through affecting intracellular lipoprotein trafficking. Collectively, our results indicate that Tm6sf2 expression level is an important determinant of cellular and organismal ApoBlipoprotein metabolism and associated morbidities. Strikingly, the metabolic constellation observed in Tm6sf2-overexpressing mice recapitulates the phenotypic consequences of Tm6sf2 deficiency and suggests that AAV-Tm6sf2 mice characterized in our study in fact represent a loss-offunction model. While this conclusion is unexpected, examples of phenocopy between overexpression and deficiency models have been documented and often involve proteins that are part of multiprotein complexes whose function is disrupted by stoichiometric imbalance (24, 25) . Thus, we hypothesize that Tm6sf2 function depends on interactions with other proteins, and both excess and deficiency of Tm6sf2 may interfere with the formation of a molecular complex required for normal cellular function. Identification of Tm6sf2-interacting proteins and better understanding of its molecular function will be required to substantiate this hypothesis.
The TM6SF2 chromosomal region is associated with plasma TG and cholesterol levels in multiple human populations (2, 3, 5) and AAV-Tm6sf2 mice reflected these phenotypes. Tm6sf2 overexpression markedly reduced plasma TG levels by suppressing hepatic VLDL-TG production. Tm6sf2 overexpression suppressed plasma ApoB levels in mice and diminished APOB secretion in hepatocytes in vitro suggesting that reduced VLDL particle secretion may be the underlying mechanism. However, as hepatic ApoB release was not directly assessed in our study, we cannot exclude the possibility of impaired VLDL lipidation as the cause of reduced VLDL-TG secretion, as has been reported in Tm6sf2-deficient mice (15) . In fact, our observation that the rate of VLDL-cholesterol secretion remained unaffected in AAV-Tm6sf2 mice is consistent with the latter possibility. Clearly, further studies will be required to clarify the molecular mechanisms responsible for impaired hepatic TG secretion in the context of Tm6sf2 overexpression. AAV-Tm6sf2 mice also exhibited lower non-HDL (i.e. VLDL and LDL) cholesterol levels, which is a likely reflection of reduced ApoB-lipoprotein particle number in the circulation. Interestingly, HDL-cholesterol was also diminished in AAV-Tm6sf2 mice. As TG-rich lipoproteins play a role in HDL maturation (26, 27) , we hypothesize that this phenotype is a consequence of reduced ApoB-lipoprotein availability in AAV-Tm6sf2 mice. Taken together, the plasma lipid phenotypes in AAV-Tm6sf2 mice are similar to those observed in Tm6sf2 knock-out and knock-down mice (3, 15) indicating that excess Tm6sf2 resulted in functional deficiency of the corresponding molecular pathway in our mouse model.
A previous study reported elevated plasma TG and cholesterol levels after adenoviral overexpression of human TM6SF2 (2) . As this observation is in direct conflict with our results, we investigated the impact of several experimental parameters differing between the studies. We determined that the use of different Tm6sf2 isoforms (i.e. human versus mouse) for transgene expression is the likely source of discordant results. Side-byside comparisons revealed that expression of the human, but not mouse, isoform resulted in hepatitis and liver injury likely reflecting immunogenicity of the human protein. Thus, plasma lipid phenotypes associated with the overexpression of human TM6SF2 may have been confounded by effects of hepatic inflammation, a pathology known to elevate TG and cholesterol levels (28, 29) .
Genetic variation in the human TM6SF2 gene is associated with pathological features of NAFLD including steatosis, steatohepatitis and fibrosis (2, 3, 10, 12, 13) . AAV-Tm6sf2 mice recapitulated early aspects of the NAFLD pathology including hepatic lipid accumulation and elevated plasma ALT levels. Hepatic accumulation of neutral lipids has also been reported in Tm6sf2-deficient mouse models (3, 15) providing further support to the idea that Tm6sf2 overexpression leads to loss-of-function phenotypes. As in Tm6sf2 deficiency, overexpression had no detectable transcriptional impact on genes involved in lipid biosynthesis, uptake or oxidation. Although we cannot exclude post-transcriptional effects on these processes, our results suggest that steatosis in AAV-Tm6sf2 mice is due, at least in part, to reduced hepatic VLDL-TG export. In contrast to genes involved in lipid homeostasis, Tm6sf2 overexpression resulted in the upregulation of several markers of inflammation and fibrogenesis 12 weeks after virus injection, although histological signs of hepatitis and fibrosis could not be detected at this timepoint. Thus, AAV-Tm6sf2 mice represent a novel model for the development of initial stages of NAFLD. Dietary manipulations and/or the use of susceptible genetic backgrounds in future studies may allow extension of the model to more advanced stages of the disease.
Through the characterization of Ldlr -/-;ApoB 100/100 (DKO) mice, we demonstrated for the first time the role of Tm6sf2 in atherosclerosis. Our results suggest that Tm6sf2 exerts its effect through the modulation of atherogenic (i.e. ApoB-containing) lipoproteins and may be responsible for the association of corresponding chromosomal region with myocardial infarction in human populations (2) . Notably, the impact of Tm6sf2 overexpression on plasma TG and cholesterol levels is more pronounced in DKO (80-90% reduction) than wild-type (50-60% reduction) mice. The dramatic reduction in plasma lipids in DKO mice may be due to upregulation of Ldlr-independent pathways of ApoB-lipoprotein clearance (30) (31) (32) . Alternatively, as DKO mice express ApoB-100, but not ApoB-48, our results may suggest that the metabolism of ApoB-100-containing lipoproteins is more dependent on Tm6sf2 function than that of ApoB-48. Interestingly, differential effects of Tm6sf2 on ApoB isoforms have also been documented in Tm6sf2-deficient mice, which exhibit elevated hepatic secretion and plasma levels of ApoB-48, but not ApoB-100 (15) . Taken together, these results suggest that Tm6sf2 functionally interacts with ApoBlipoproteins in an isoform-specific manner. Identification of the underlying mechanisms in future studies may shed new light on the molecular function of Tm6sf2. Under physiological conditions, VLDL secretion is principally regulated by pathways mediating the intracellular degradation of ApoB (33, 34) . However, it is clear that increased degradation is not responsible for impaired ApoB secretion in the context of Tm6sf2 overexpression, as cellular ApoB protein levels are not reduced, but in fact elevated in liver as well as in cultured hepatocytes. The cellular accumulation of ApoB implies that initial lipidation of the protein is not impaired in cells overexpressing Tm6sf2. Moreover, our observation that ApoB is trapped within the ER of these cells indicates that excess Tm6sf2 interferes with the release of ApoB-lipoprotein particles from the organelle. ER-to-Golgi transport of ApoB-lipoproteins is mediated by a molecular machinery orchestrating the recruitment of pre-VLDL cargo to ER exit sites and packaging into specialized VLDL transport vesicles (VTV) (35) . As Tm6sf2 is localized to the ER, ERGIC and Golgi (15, 16) , its overexpression may directly affect ER-to-Golgi trafficking of pre-VLDL particles. It is conceivable that Tm6sf2 interacts with a critical component of the protein complex mediating VTV assembly/release and titration of this component by excess Tm6sf2 may disrupt lipoprotein export from the ER. Consistent with a role in VLDL trafficking, TM6SF2 deficiency reduced APOB secretion in cultured human hepatocytes (16) . In contrast, a recent report demonstrated that Tm6sf2 deficiency impairs the lipidation, but not secretion of ApoB-lipoprotein particles (15) . The reason for discrepancy between the two studies is currently unclear. Thus, while both overexpression and deficiency of Tm6sf2 suppress VLDL-TG secretion (3, 15) , the underlying molecular mechanisms may be different. Collectively, these results implicate Tm6sf2 in the intracellular transport and lipidation of VLDL particles and may identify a previously unrecognized molecular link between these processes.
While investigating the metabolic role of Tm6sf2 in genetically engineered mouse models has been a primary focus of recent studies, the functional consequences of naturally occurring genetic variation in the human TM6SF2 gene have not been fully explored. Genome-and exome-wide association studies identified two coding variants (L156P and E167K) in TM6SF2 to be independently associated with plasma lipids, NAFLD and alcoholinduced cirrhosis (2, 3, 5, 8) . We determined that rare alleles of both variants (i.e. P156 and K167) increased the rate of turnover and markedly reduced steady state cellular levels of TM6SF2. These results confirm that L256P and E167K are functional variants, and suggest that their association with plasma lipid levels and fatty liver disease is mediated by altered TM6SF2 protein expression. Furthermore, we demonstrate for the first time that the rare alleles of these polymorphisms represent loss-of-function variants. As P156 and K167 are associated with lower plasma lipid levels in humans, our results also indicate that loss of TM6SF2 function is the underlying mechanism; a conclusion consistent with mouse models of Tm6sf2 deficiency (3, 15) . Amino acid L156 is evolutionarily conserved among paralogous members of the EXPERA protein family (18) and located within one of the predicted helical transmembrane domains of TM6SF2. Thus, substitution of L156 with proline, a helix breaker, likely interferes with insertion of the domain into the membrane, alters overall TM6SF2 topology and leads to decreased stability and increased degradation of the protein. E167K is a charge-altering amino acid substitution, which may impair protein stability by altering overall protein structure. However, the closest homolog of TM6SF2, TM6SF1, harbors a positively charged residue (i.e. arginine) at position 167, which makes this explanation unlikely (18) . Thus, we favor the alternative possibility that E167K disrupts interaction with another protein that is critically required for the stability of TM6SF2. Future studies will be required to explore this hypothesis. In conclusion, our results demonstrate that rs187429064 (L156P) and rs58542926 (E167K) are causative genetic variants and exert their effects on lipid metabolism at least in part through the modulation of TM6SF2 protein abundance.
In the present study, we demonstrated that elevated hepatic Tm6sf2 expression has significant impact on plasma lipoproteins, atherosclerosis and fatty liver disease. The observation that both excess and deficiency of Tm6sf2 lead to altered lipid metabolism indicates that the level of Tm6sf2 expression is an important determinant of metabolic homeostasis. Indeed, we have shown that SNPs associated with metabolic traits in human populations alter cellular TM6SF2 protein levels. An unexpected finding of our study is that Tm6sf2 overexpression resulted in metabolic phenotypes that have previously been observed in loss-of-function models. Deciphering the underlying mechanisms in future studies may shed new light on the molecular function and interactions of Tm6sf2 in the regulation of ApoB-lipoprotein metabolism.
Materials and Methods
Mice
C57BL/6J and Ldlr -/-;ApoB 100/100 (referred to as DKO) mice were obtained from The Jackson Laboratory (stock #003000) and bred in-house. Animals were maintained on a 14-h light/10-h dark cycle and fed ad libitum Laboratory Rodent Diet 5053 (LabDiet), a high-fat diet (D12492; 60 kcal% from lard; Research Diets) or a HC diet (TD 88137; 0.2% cholesterol; Harlan Teklad) with free access to water. Unless otherwise noted, mice were fasted for 4 h (8:00 am to 12:00 pm) before blood collection. For overnight fasting, mice were deprived of food for 16 h (6:00 pm to 10:00 am). All experimental procedures were approved by the Institutional Animal Care and Use Committees at Cedars-Sinai Medical Center and Western University.
AAV-mediated expression
Mouse and human TM6SF2 coding cDNA sequences without epitope tag were used to replace eGFP in the pENN.AAV.TBG.PI.eGFP vector (p1014; Penn Vector Core), which drives expression from the TBG promoter. AAV serotype 8 (AAV8) particles were packaged and purified on a fee-for-service basis at the Penn Vector Core (Perelman School of Medicine, University of Pennsylvania). Empty (AAV-Null) or eGFP-expressing [AAV-green fluorescent protein (GFP)] vectors were used as controls. AAV8 particles were intravenously injected through the retro-orbital sinus at a dose of 10 12 gc per mouse, unless otherwise noted.
Plasma and liver chemistries
For plasma lipid and lipoprotein analyses, blood was collected from mice after 4 h fasting. Plasma lipid levels were determined as described (36) . To assess lipoprotein distribution, equal volumes of plasma from three to eight mice were pooled and analyzed by size fractionation on a FPLC column at the Mouse Metabolic Phenotyping Center at Vanderbilt University School of Medicine. Plasma ALT activity and bilirubin concentration were determined by colorimetric assays (Pointe Scientific and Sigma-Aldrich, respectively). Lipids were extracted from pieces of liver (50-100 mg) using the Folch method (37) followed by enzymatic analysis of TG, total cholesterol and free cholesterol, as described (38) .
Hepatic TG secretion
After 4 h fasting, AAV-treated mice were intraperitoneally injected with 1 mg/g body weight of Pluronic F-127 (Sigma) to block vascular TG hydrolysis by lipoprotein lipase (39) . Blood was obtained by retro-orbital bleeding before and 1 or 2 h after injection followed by analyses of TG and cholesterol (Amplex 
MTTP activity assay
Liver ($100 mg) or Huh7 cells grown in 6-well plates were homogenized and assayed using fluorescently labeled triglyceride substrate as described previously (40) .
Assessment of atherosclerotic lesions
After 12 weeks of HC diet feeding, mice were anesthetized with isoflurane and the aorta and heart were excised. Aortas were excised from the aortic arch to the iliac bifurcation. En facemounted aortas, aortic sinus and aortic arch sections were prepared and stained with ORO as previously described (41, 42) . Lesion and ORO-stained areas were quantified as described (43) . As no differences between sexes were observed, data from male and female mice have been combined and analyzed together.
RNA analysis
mRNA levels were determined by real-time PCR analysis as described (44) using 36B4 as internal control. Primer sequences are available upon request.
Cell culture studies
Cellular lipoprotein metabolism was assessed in human hepatoma cell lines (Huh7, HepG2 and Hep3B) obtained from the American Type Culture Collection and grown under standard culture conditions. Primary human HLCs were derived by differentiating an iPSC line (83i-CTRL) established at the Cedars-Sinai Medical Center iPSC Core as described (45, 46) . Cell lines were periodically tested negative for mycoplasma contamination. To generate stable cell lines, a lentiviral vector (pFG.EF1.m Cherry.IRES.Puro.WPRE) was used to express mCherry (mCh) or V5-TM6SF2 under the control of the EF1 promoter. Cell lines were maintained in media supplemented with 2 lg/ml puromycin. APOB secretion was assessed by incubating sub-confluent cells cultured in triplicate wells of 48-well plates for 4-6 h in fresh media. APOB secretion from Huh7 and HepG2 cells has previously been found to be linear for up to 24 h with no evidence of reuptake of secreted lipoproteins (16) . APOB concentrations in cell culture media were quantitated using an ELISA kit (3715-1H-6; Mabtech) according to the manufacturer's instructions. To normalize for cell number and control for non-specific effects affecting secretion, albumin secretion was also determined (E80-129; Bethyl Laboratories) from an aliquot of the same samples. For transient overexpression, Hep3B cells or HLCs were infected (MOI ¼ 10-40) with adenoviral vectors expressing TM6SF2 or mCherry under control of the CMV promoter. APOB and albumin secretion assays were conducted 2 days after adenoviral transduction. Transduced Hep3B cells (three wells per condition) were treated with either BSA or a BSA:OA complex (1:5 molar ratio; 0.6 mM OA) for 8 h, lactacystin (Lacta, 10 mM; Sigma), 3-methyladenine (3-MA, 5 mM; Cayman Chemical) or vehicle (DMSO) for 4 h. After treatment, media were replaced with fresh media, which was then collected 4 h later for APOB/albumin analysis.
For the measurement of intracellular APOB, cells cultured in 6-well plates were rinsed in PBS and resuspended in lysis buffer (100 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, protease inhibitors). APOB in cell lysates was assayed with ELISA based on the 1D1 monoclonal antibody, which recognizes lipid-free and lipid-associated APOB with equal affinity (47) .
Western blot analyses
To detect ApoB in liver, tissue samples were homogenized in a buffer containing 62 mM sucrose, 0.5% sodium deoxycholate, 0.5% Triton X-100, 5 mM EDTA, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl (pH 7.4) and protease inhibitors. One hundred micrograms of liver lysates were fractionated by 6% SDS-PAGE followed by transfer to nitrocellulose membrane. Following blocking with 5% milk, membranes were incubated with a rabbit anti-mouse ApoB antibody (K23300R, Meridian Life Science; 1:1000 dilution) at 4 C overnight and Alexa Fluor 633-conjugated goat antirabbit IgG antibody (A-21070, ThermoFisher; 1:10 000 dilution) at room temperature for 1 h. Blots were visualized with a Storm 640 device (Amersham). For normalization of ApoB signal, blots were re-probed with monoclonal anti-vinculin antibody (Sigma V9131; 1:1000 dilution) and goat anti-mouse IgG antibody (A-21050, ThermoFisher; 1:10 000 dilution). Mouse plasma was similarly analyzed after SDS-PAGE separation of equal sample volumes representing 0.5 ll of plasma.
To detect V5 epitope-tagged TM6SF2 in Huh7 cells, cells cultured in six-well plates were lysed (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP40, protease inhibitors), separated by 10% SDS-PAGE and transferred to PVDF membrane. After blocking, membranes were probed with mouse monoclonal anti-V5 (R960-25, ThermoFisher; 1:10 000 dilution) and HRP-conjugated rabbit anti-mouse IgG (315-035-003, Jackson ImmunoResearch; 1:100 000 dilution) antibodies. For normalization, membranes were reprobed with rabbit anti-HSP90 (sc-7947, Santa Cruz Biotechnology; 1:1000 dilution) and HRP-conjugated donkey anti-rabbit IgG (711-035-152, Jackson ImmunoResearch; 1:100 000 dilution) antibodies. Bands were visualized using the SuperSignal West Femto chemiluminescent substrate (ThermoFisher).
Subcellular localization of APOB
